Galectin Therapeutics Inc

NASDAQ:GALTUnited States

Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company's lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the United States Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.

Contact Information

Headquarters

SUITE 240 4960 PEACHTREE INDUSTRIAL BOULEVARDNORCROSS, GA, United States 30071

Phone

678-620-3186

Fax

770-864-1327

Executives

Independent Chairman of the Board

Richard Uihlein

President, Chief Executive Officer, Director

Joel Lewis

Chief Financial Officer

Jack Callicutt

Chief Medical Officer

Khurram Jamil

Director

Benjamin Carson